Raymond James Financial
SRPT icon

Raymond James Financial’s Sarepta Therapeutics SRPT Stock Holding History

Raymond James Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,742
Closed -$212K – 5571
2026
Q1 		$212K Sell
9,742
-1,333
-12% -$25.8K ﹤0.01% 4859
2025
Q4 		$238K Sell
11,075
-822
-7% -$17.3K ﹤0.01% 4703
2025
Q3 		$229K Buy
11,897
+114
+1% +$2.03K ﹤0.01% 4554
2025
Q2 		$201K Sell
11,783
-351,112
-97% -$15M ﹤0.01% 4516
2025
Q1 		$23.2M Sell
362,895
-33,924
-9% -$3.57M 0.01% 1194
2024
Q4 		$48.2M Buy
+396,819
New +$48.6M 0.02% 745

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Raymond James Financial's SRPT Position: Q2 2026 in Review

Raymond James Financial sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 9,742 shares — an estimated $212K sold.

Raymond James Financial first reported a position in SRPT in Q4 2024 and held it in 6 quarters. The position peaked at $48.2M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Raymond James Financial reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 9,742 Sarepta Therapeutics shares in Q2 2026, an estimated $212K.
  • Raymond James Financial first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's Sarepta Therapeutics position peaked at $48.2M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.